Sevoflurane Baxter 100 mg Liquid for inhalation
PDF Leaflet Revision Date: 13 April 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Induction and maintenance of general anaesthesia.
Dosage (summary)
Individualised; typically 0.5-3% for maintenance.
Onset of Action / Duration
Onset: <2 mins, Duration: variable.
Special Populations
- Elderly
- Paediatric patients
- Renal impairment
- Liver disease
- Mitochondrial disorders
Pregnancy & Breastfeeding
Caution in pregnancy; safety not established. Unknown if excreted in breast milk.
Key Drug Interactions
- Nitrous oxide decreases MAC
- Benzodiazepines and opioids may enhance effects
- Neuromuscular blockers require dosage adjustment
Contraindications
- Hypersensitivity to sevoflurane
- History of malignant hyperthermia
- Neuromuscular disease
- General anaesthesia contraindicated
Common side effects
- Nausea
- Vomiting
- Dizziness
- Hypotension
- Bradycardia
Counselling Points
- Avoid driving for 24 hours post-anaesthesia
- Monitor for signs of respiratory depression
- Inform about potential for postoperative nausea
Serious warnings
- Respiratory depression risk
- Potential for malignant hyperthermia
- Caution in patients with coronary disease
Important Disclaimer
The Sevoflurane Baxter 100 mg Liquid for inhalation professional information leaflet below is the property of Baxter Healthcare South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
